<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885426</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-019</org_study_id>
    <nct_id>NCT04885426</nct_id>
  </id_info>
  <brief_title>Metformin for the Prevention of CRA Recurrence</brief_title>
  <official_title>The Role of Metformin in the Prevention for Colorectal Adenoma Recurrence in Post-polypectomy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing-yuan Fang, MD, Ph. D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the sporadic colorectal cancer (CRC )develop from colorectal adenoma (CRA), patients&#xD;
      with CRA have a high risk of recurrence and development of metachronous CRA or CRC after&#xD;
      removal, therefore, the investigators conducted this clinical trial to explore the&#xD;
      chemoprevetion effect of metformin for CRA recurrence after removal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal&#xD;
      cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for&#xD;
      colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer&#xD;
      have been established. Because of the high recurrence rates of colorectal adenomas in&#xD;
      patients who have undergone polypectomy, the potential chemopreventive agents that may reduce&#xD;
      the risk of colorectal adenoma recurrence need to be investigated.&#xD;
&#xD;
      Metformin is a widely used diabetes medicine. In recent years, anticancer activity of&#xD;
      metformin has been explored. The aim of this study is to investigate the effect of metformin&#xD;
      on the recurrence of colorectal adenomas by conducting a randomized, placebo-controlled,&#xD;
      prospective clinical.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant, investigator, data analyst, endoscopist and pathologist involved in this study are all blinded of which treatment the participants are receiving. The pharmaceutical company provided blinded bottles of study pills with the label 'A' , 'B' or 'C'. Unblinding will be advanced only in case of emergency.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CRA recurrence rate</measure>
    <time_frame>one year, two years</time_frame>
    <description>Percentage of patients who has recurrence of CRA(colorectal adenoma) during or after chemotherapy with metformin or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All polypoid lesions incidence rate</measure>
    <time_frame>one year, two years</time_frame>
    <description>Percentage of patients who has incidence of all polypoid lesions during or after chemotherapy with metformin or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRC incidence rate</measure>
    <time_frame>one year, two years</time_frame>
    <description>Percentage of patients who has incidence of CRC (colorectal cancer) during or after chemotherapy with metformin or placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Colorectal Adenoma</condition>
  <condition>Metformin</condition>
  <condition>Chemoprevention</condition>
  <arm_group>
    <arm_group_label>low-dose metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose metformin, 250mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high-dose metformin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-dose metformin, 500mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose metformin</intervention_name>
    <description>Metformin Pill 250mg/day</description>
    <arm_group_label>low-dose metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose metformin</intervention_name>
    <description>Metformin Pill 500mg/day</description>
    <arm_group_label>high-dose metformin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 40-80 years without diabetes;&#xD;
&#xD;
          2. CRAs removed without recurrence before recruitment;&#xD;
&#xD;
          3. Must sign the consent form after being fully informed and understanding the purpose&#xD;
             and procedure of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer&#xD;
             (HNPCC, Lynch syndrome);&#xD;
&#xD;
          2. Regularly taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs),&#xD;
             cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D;&#xD;
&#xD;
          3. Have a history of gastrointestinal surgery;&#xD;
&#xD;
          4. Have severe heart, liver or kidney disease ;&#xD;
&#xD;
          5. Have cancer history;&#xD;
&#xD;
          6. Women with pregnant, during breast-feeding period, or with expect pregnancy;&#xD;
&#xD;
          7. Diabetesï¼ˆtaking diabetes medicines or HbA1c&gt;6.5%);&#xD;
&#xD;
          8. Inflammatory bowel disease;&#xD;
&#xD;
          9. Mental illness;&#xD;
&#xD;
         10. Intolerant to metformin;&#xD;
&#xD;
         11. Cannot tolerate colonoscopy;&#xD;
&#xD;
         12. Staffs in this clinical trial;&#xD;
&#xD;
         13. Poor bowel preparation for colonoscopy or the examination time is shorter than 6&#xD;
             minutes;&#xD;
&#xD;
         14. Unsuitable for inclusion by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing-Yuan Fang, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing-Yuan Fang, Professor</last_name>
    <phone>+8613918386561</phone>
    <email>jingyuanfang@sjtu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Ren-Ji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology &amp; Hepatology, Ministry of Health</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing-Yuan Fang, MD. Ph D.</last_name>
      <phone>+863386235037</phone>
      <email>wangjilin811123@163.com</email>
    </contact>
    <investigator>
      <last_name>Jing-Yuan Fang, MD. Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jing-yuan Fang, MD, Ph. D</investigator_full_name>
    <investigator_title>Director of Department of Gastroenterology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

